Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $26 price target.
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $26 price target.